🏆 Deal of the Month · May 2026
Isomorphic Labs raised USD 2.1 billion in a Series B round; the company's valuation was not disclosed. The round closed in May 2026. It was led by Thrive Capital.
Isomorphic Labs — key deal facts
| Company | Isomorphic Labs |
| Founded | 2021 |
| Headquarters | London, United Kingdom |
| Amount raised | USD 2.1b |
| Valuation | Valuation Remains Undisclosed |
| Round | Series B |
| Investors | The round was led by Thrive Capital, and includes participation from existing backers Alphabet and GV alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund |
| Sectors | AI, BioTech, Pharmaceutical |
Who invested in Isomorphic Labs?
The round includes participation from existing backers Alphabet and GV alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. The investor mix is notable for combining sovereign and institutional capital from multiple continents with deep-pocketed strategic backers already embedded in the Alphabet ecosystem. The presence of the UK Sovereign AI Fund also signals direct government-level conviction in AI-driven drug discovery as a national strategic priority.
What does Isomorphic Labs do?
Isomorphic Labs is an AI-driven drug discovery company founded in 2021 by Demis Hassabis and headquartered in London, United Kingdom. The company operates at the intersection of artificial intelligence, biotechnology, and pharmaceuticals, applying predictive and generative models — including AlphaFold 3 — to design novel molecules and anticipate drug performance. Its flagship product, IsoDDE (Isomorphic Drug Design Engine), functions as a unified AI drug design platform aimed at accelerating the path from target identification to candidate molecule across a wide range of diseases. Isomorphic Labs operates as a subsidiary of Alphabet Inc. and draws on an interdisciplinary team of machine learning specialists and drug discovery scientists.
Isomorphic Labs valuation & multiples
Isomorphic Labs operates at the intersection of biotechnology, artificial intelligence, and pharmaceuticals, with a specific focus on accelerating drug discovery through advanced AI models and computational life sciences research. European benchmarks for AI-enabled biotechnology and pharmaceutical businesses at Series B stage (Q1 2026) indicate EV/Sales multiples of 3.61x–4.99x and EV/EBITDA multiples of 16.84x–20.68x. Investors seeking deeper context on how these ranges compare across the sector can explore the AI, BioTech, and Pharmaceutical multiples pages on DealMatrix.
Explore the benchmarks: Series B Pharmaceutical.
Frequently asked questions
How much did Isomorphic Labs raise in its Series B?
Isomorphic Labs raised USD 2.1 billion in its Series B round in May 2026.
What is Isomorphic Labs's valuation?
Isomorphic Labs's valuation was not disclosed in connection with this Series B round.
Who invested in Isomorphic Labs?
The Series B was led by Thrive Capital, with participation from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.
When was Isomorphic Labs founded and where is it based?
Isomorphic Labs was founded in 2021 and is headquartered in London, United Kingdom.
Source: original announcement — read the full report.